Clinical trials
Phase 3 Lymphoma, Mantle-Cell trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2004 | 2 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2016 | 2 |
| 2021 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 18 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Mantle Cell Lymphoma Network | 2 |
| Prof. Dr. M. Dreyling (co-chairman) | 2 |
| Shandong Provincial Hospital | 2 |
| Clatterbridge Centre for Oncology | 1 |
| Commissie Voor Klinisch Toegepast Onderzoek | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Fondazione Italiana Linfomi - ETS | 1 |
| German Low Grade Lymphoma Study Group | 1 |
| Gilead Sciences | 1 |
| Jonsson Comprehensive Cancer Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, Mantle-Cell | 18 |
| Lymphoma, Large B-Cell, Diffuse | 10 |
| Lymphoma, Follicular | 9 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 8 |
| Burkitt Lymphoma | 7 |
| Lymphoma | 7 |
| Lymphoma, B-Cell, Marginal Zone | 6 |
| Lymphoma, Large-Cell, Immunoblastic | 6 |
| Lymphoma, Non-Hodgkin | 6 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.